1. Medicine

Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical

  1. Elisabeth Gludovacz
  2. Kornelia Schuetzenberger
  3. Marlene Resch
  4. Katharina Tillmann
  5. Karin Petroczi
  6. Markus Schosserer
  7. Sigrid Vondra
  8. Serhii Vakal
  9. Gerald Klanert
  10. Jürgen Pollheimer
  11. Tiina A Salminen
  12. Bernd Jilma
  13. Nicole Borth
  14. Thomas Boehm  Is a corresponding author
  1. Department of Biotechnology, University of Natural Resources and Life Sciences, Austria
  2. Department of Clinical Pharmacology, Medical University of Vienna, Austria
  3. Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria
  4. Center for Biomedical Research, Medical University of Vienna, Austria
  5. Department of Obstetrics and Gynecology, Medical University of Vienna, Austria
  6. Strutural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Finland
https://doi.org/10.7554/eLife.68542
Share this article
Cite this article
  1. Elisabeth Gludovacz
  2. Kornelia Schuetzenberger
  3. Marlene Resch
  4. Katharina Tillmann
  5. Karin Petroczi
  6. Markus Schosserer
  7. Sigrid Vondra
  8. Serhii Vakal
  9. Gerald Klanert
  10. Jürgen Pollheimer
  11. Tiina A Salminen
  12. Bernd Jilma
  13. Nicole Borth
  14. Thomas Boehm
(2021)
Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical
eLife 10:e68542.
https://doi.org/10.7554/eLife.68542
  2. Download BibTeX
  3. Download .RIS
6 figures, 4 tables and 2 additional files

Figures

Figure 1
Download asset Open asset
Recombinant human diamine oxidase (rhDAO) efficiently degrades histamine in phosphate buffered saline (PBS) and human plasma samples from mastocytosis patients and healthy volunteers.

(A) 6 nM purified rhDAO-WT with and without 100× high molecular weight heparin (HMWH; 600 nM) were incubated at 37°C for 60 min with 100 ng/mL histamine in 1% human serum albumin-phosphate buffered saline (HSA-PBS) and EDTA plasma of a healthy volunteer. Histamine concentrations were determined in duplicate. Plasma: △; plasma with 100× HMWH: ◇; HSA-PBS: ○; HSA-PBS with 100× HMWH: □. (B) Plasma of mastocytosis patients (n = 7) and healthy volunteers (n = 3) was spiked with 6 nM rhDAO-WT, 545 nM histamine, and 20 µM diminazene aceturate (DZ, potent DAO inhibitor) and incubated for 60 min at 37°C. Mean histamine concentrations with standard deviation (SD) as applicable are shown; column Pl (plasma): no histamine and no DAO spiking but with endogenous histamine; column Pl/His/DAO: spiking of exogenous histamine and exogenous DAO; column Pl/His: spiking of exogenous histamine; column Pl/His/DAO/DZ: spiking of exogenous histamine, DAO, and DIMAZ; t-test p-value comparing Pl with Pl/His/DAO data was 0.015 for mastocytosis patients and 0.011 for healthy volunteers; Histamine concentrations in Pl/His and Pl/His/DAO/DZ samples were >500 nM and the SD could not be calculated. Pl: plasma; His: histamine.

Figure 2
Download asset Open asset
Mutations of the heparin-binding motif of recombinant human diamine oxidase (rhDAO) significantly reduce binding to heparin and heparan sulfate (HS).

(A) Purified rhDAO-WT and various heparin-binding motif (HBM) mutants were loaded onto a heparin-sepharose column and eluted with a linear gradient of increasing NaCl concentration. (B) Isothermal titration calorimetry was performed by titrating 25 × 1.5 µL high molecular weight heparin (HMWH) at a concentration of 120 µM into 36.7 µM rhDAO-WT (○) or rhDAO-R568S/R571T (△). The graph represents single experiments for each protein-ligand pair. A summary of all experiments is shown in Figure 2—source data 1. (C) Biolayer interferometry. Streptavidin sensors loaded with biotinylated HMWH or HS were incubated for 10 min with 88 nM or 471 nM rhDAO, respectively. Dissociation was measured for 15 min. The graphs represent one of three individual measurements and show the association and dissociation curves after subtraction of the negative control (no DAO added). The data of rhDAO-WT have already been published (Gludovacz et al., 2020) but are added for better presentation.

Figure 2—source data 1

All raw plots and integrated heat plots of the isothermal titration calorimetry (ITC) analyses of the heparin-binding motif (HBM) mutant are presented in Figure 2B.

https://cdn.elifesciences.org/articles/68542/elife-68542-fig2-data1-v3.docx
Figure 3
Download asset Open asset
Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) double mutants show significantly reduced uptake into various cell lines.

(A) SK-Hep1, primary human umbilical vein endothelial cells ( = HUVECp), human dermal fibroblasts (HDF), HepG2, and HeLa cells were incubated with 120 nM unlabeled purified rhDAO-WT and various HBM mutants and detected with rabbit anti-ABP1 antibodies and Alexa Fluor 488 donkey anti-rabbit antibodies after fixation and permeabilization. Immortalized HUVEC/TERT2 ( = HUVECi) and human dermal microvascular endothelial cells (HDMVEC/TERT164-B = HDMVECi) were incubated with 120 nM and extravillous trophoblasts (EVT) with 60 nM Alexa488-labeled rhDAO-WT and rhDAO-R568S/R571T; Scale bar = 20 μm. (B) Cells were incubated with 30 nM Alexa488-labeled rhDAO-WT and rhDAO-R568S/R571T mutant (no DAO added = negative control), washed, and analyzed flow cytometrically (500 cells per sample). Background corrected mean median values ± standard error of the mean (SEM) are shown (n = 4 biological replicates, two individual experiments in duplicate). (C) 106 SK-Hep1 and 5 × 105 HUVEC/TERT2 cells were incubated with 120 nM and 60 nM rhDAO-WT and three HBM mutants. The cell lysates were analyzed for DAO uptake using western blotting. β-Actin was used as an internal standard. (D) After background subtraction, rhDAO band intensities were corrected against β-Actin and normalized against the rhDAO-WT band. The mean ± SEM of two individual experiments with SK-Hep1 cells and one experiment with HUVEC/TERT2 cells are shown. (A–D) Incubations were performed for 60 min at 37°C. FI: fluorescence intensity; AU: arbitrary units.

Figure 3—source data 1

Statistical evaluation of flow cytometry data is summarized in Figure 3B.

https://cdn.elifesciences.org/articles/68542/elife-68542-fig3-data1-v3.docx
Figure 3—source data 2

Raw unedited western blots are presented in Figure 3C.

https://cdn.elifesciences.org/articles/68542/elife-68542-fig3-data2-v3.docx
Figure 4
Download asset Open asset
Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) mutants show strongly reduced clearance compared to the wildtype protein in rats and mice.

(A, B) Reduced clearance of HBM mutants in rats. Means of the measured values ± standard deviation (SD) after administration of 1 mg/kg purified rhDAO: (A) WT (n = 9; □), -R568S (n = 4; ■), -R568S/R571T (n = 5; ●), -R568S/K575T (n = 4; △); (B) rhFcDAO (n = 6; □), Fc-R568S/R571T (n = 4; ●). (C, D) rhDAO-R568S/R571T mutant increases the area under the curve (AUC) more than 15-fold compared to wildtype rhDAO after intravenous and intraperitoneal injection into mice. (C) rhDAO-WT (□) and rhDAO-R568S/R571T (●) were injected at 1 mg/kg into the tail vein of C57BL6 mice with a body weight of about 20 g. The mean (n = 3–4 mice per time point) ± SD are shown. (D) rhDAO-WT and rhDAO-R568S/R571T mutant were injected intraperitoneally at 1 mg/kg in mice with a body weight of 21 g. Each time point represents the mean of 3 mice, and therefore in total 15 mice with WT and 15 mice with rhDAO-R568S/R571T were used. The means ± SD are shown. n: number of animals.

Figure 5 with 2 supplements
Download asset Open asset
Recombinant human diamine oxidase (rhDAO) heparin-binding motif (HBM) mutants are enzymatically fully active in vitro and in vivo.

(A) Purified rhDAO-R568S/R571T mutant rapidly and completely degrades histamine. 6 nM rhDAO-R568S/R571T with and without 100× high molecular weight heparin (HMWH) (600 nM) were incubated with 100 ng/mL histamine in 1% human serum albumin-phosphate buffered saline (HSA-PBS) and EDTA plasma of a healthy volunteer for 60 min at 37°C. Histamine concentrations were determined in duplicate. Plasma: △; plasma with 100× HMWH: ◇; HSA-PBS: ○; HSA-PBS with 100× HMWH: □. (B–D) rhDAO HBM mutants are enzymatically active in rats. Means of the measured values ± standard error of the mean (SEM) using 1 mg/kg rhDAO-R568S/R571T (B, n = 3; R2 = 94.8% with p-value<0.001, linear regression) and rhFcDAO-R568S/R571T (D, n = 3; R2 = 98% with p-value<0.001, linear regression) and two individually plotted measurements of rhDAO-R568S/K575T (C); rhDAO concentration (ng/mL; □ and ○) and activity (relative fluorescence units [RFU]; ■ and ●); RFU data downscaled by a factor 50 in panels (B) and (C) and by 100 in (D) for easier presentation. n: number of animals.

Figure 5—figure supplement 1
Download asset Open asset
Recombinant human diamine oxidase (rhDAO) antigen concentrations and activity are highly correlated in rat plasma.

Means of the measured values using 1 mg/kg rhDAO-R568S/R571T (A, n = 3) and Fc-rhDAO-R568S/R571T (C, n = 3) and two individually plotted measurements of rhDAO-R568S/K575T (B); relative fluorescence units (RFU) data downscaled by factor 50 in panels (A) and (B) and by factor 100 in (C). n: number of animals.

Figure 5—figure supplement 2
Download asset Open asset
The enzymatic activity of rhDAO-R568S/R571T is comparable to rhDAO-WT.

Enzymatic activity of rhDAO-WT (□) and rhDAO-R568S/R571T (●) at 0.7 nM, 2 nM, and 6 nM was measured as published (Boehm et al., 2020; Boehm et al., 2017). Means ± standard deviation (SD) of duplicate measurements are shown. RLU: relative light units; rhDAO: recombinant human diamine oxidase.

Figure 6 with 2 supplements
Download asset Open asset
Structural analysis of the heparin-binding motif (HBM) in the 3D models for the R568S, R571T, and R568S/R571T mutants compared with the crystal structure of hDAO-WT.

(A) Top view of the HBM in hDAO-WT. R568 and R571 (green sticks) are the key residues in the positively charged HBM formed by arginines and lysines from both chains in the hDAO-WT dimer. Intramolecular interactions formed by R571 stabilize the HBM. (B) Top view of the HBM in hDAO-R568S dimer. The positively charged area is reduced around S568s in the R568S mutant compared to hDAO-WT (A). (C) Top view of the HBM in hDAO-R571T. The stabilizing interactions formed by R571 in hDAO-WT (A) are lost, and positive patches around T571s are reduced in hDAO-R571T. (D) Complex of hDAO-WT dimer with heparin hexasaccharide, sliced side view. R568s form hydrogen bonds with heparin hexasaccharide. (E) Complex of hDAO-R568S/R571T dimer with heparin hexasaccharide, sliced side view. In the R568S/R571T mutant, the positively charged surface patches and the stabilizing interactions are lost. Red color corresponds to the negatively charged surface, blue color indicates positively charged regions. hDAO: human diamine oxidase.

Figure 6—figure supplement 1
Download asset Open asset
Structural analysis of the heparin-binding motif (HBM) in 3D models of the K575T, K570G/R571Q/K572T, and R568S/R571T mutants versus the crystal structure of hDAO-WT.

(A) HBM in hDAO-WT, top view. (B) Complex of hDAO-WT (left) and hDAO-K575T (right) dimers with heparin hexasaccharide, sliced side view. Change of lysine to threonine leads to a dramatic decrease in the positively charged surface inside the HBM. (C) Local interaction networks of K575 (chain A) in hDAO-WT and the corresponding site with T575 (chain B) of hDAO-K575T show that the mutation eliminates stabilizing hydrogen bonds. (D) Local interaction network of R568 is shown in chain A and R571 – in chain B of hDAO-WT. R568 interacts with heparin hexasaccharide, and R571 establishes multiple interactions with other residues stabilizing the HBM. (E) Local interaction networks are shown for S568 in chain A and T571 – in chain B of hDAO-R568S/R571T. The double mutation leads to an evident disruption of the hydrogen bonding network due to R571T mutation and loss of interactions with the heparin hexasaccharide due to R568S mutation. (F) Local interaction networks of K570, R571, and K572 (chain A) in hDAO-WT compared to the corresponding site in hDAO-K570G/R571Q/K572T (chain B). The triple mutation reduces the number of favorable interactions with other binding site residues and heparin hexasaccharide. (G) Top view of hDAO-WT compared to the K570G/R571Q/K572T triple mutant (chain B). The surface charge of the HBM changes from positive to negative charge in the triple mutant. Red color corresponds to the negatively charged surface, blue color indicates positively charged regions. hDAO: human diamine oxidase.

Figure 6—figure supplement 2
Download asset Open asset
Regression analysis of in silico affinity change estimations and measured heparin-sepharose salt elution concentrations of various heparin-binding motif (HBM) mutants.

Regression analysis of predicted free energy changes in heparin affinity and the NaCl concentrations necessary for the elution from heparin-sepharose of the HBM mutants rhDAO-R568S, rhDAO-K575T, rhDAO-R568S/R571T, and rhDAO-R568S/K575T versus rhDAO-WT (0 affinity; 372 mM NaCl). The rhDAO-K570G/R571Q/K572T triple mutant corresponding to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster proteins was excluded (A, p-value 0.0088), or included (B, p-value 0.08) in the calculations.

Tables

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Gene (Homo sapiens)AOC1GenBankHGNC: 80
Recombinant DNA reagentpRMCE-hDAO (plasmid)Gludovacz et al., 2016hDAO-WT expression vector
Recombinant DNA reagentpRMCE-hDAO-R568S (plasmid)This paperR568S mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO-R571T (plasmid)This paperR571T mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO-K575T (plasmid)This paperK575T mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO-R568S/R571T (plasmid)This paperR568S/R571T mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO-R568S/K575T (plasmid)This paperR568S/K575T mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO-R571T/K575T (plasmid)This paperR571T/K575T mutant of hDAO
Recombinant DNA reagentpRMCE-hDAO- K570G/R571Q/K572T (plasmid)This paperK570G/R571Q/K572T mutant of hDAO
Recombinant DNA reagentpRMCE-hFcDAO (plasmid)This paperFusion of human IgG Fc and hDAO
Recombinant DNA reagentpRMCE-hFcDAO-R568S/R571T (plasmid)This paperFusion of human IgG Fc and R568S/R571T mutant of hDAO
Sequence-based reagentR568S-FPThis paperPCR primersttcaaaaggaagctgccc
Sequence-based reagentR568S-RPThis paperPCR primersgctgaaggccgcctggc
Sequence-based reagentR571T-FPThis paperPCR primersacgaagctgcccaagtacc
Sequence-based reagentR571T-RPThis paperPCR primerstttgaagcggaaggc
Sequence-based reagentK575T-FPThis paperPCR primersacgtacctgctctttaccagcc
Sequence-based reagentK575T-RPThis paperPCR primersgggcagcttccttttga
Sequence-based reagentR568S/R571T-FPThis paperPCR primersaaaacgaagctgcccaagtacctg
Sequence-based reagentR568S/R571T-RPThis paperPCR primersgaagctgaaggccgcctgg
Sequence-based reagentR571T/K575T-FPThis paperPCR primersgcccacgtacctgctctttaccagccc
Sequence-based reagentR571T/K575T-RPThis paperPCR primersagcttcgttttgaagcggaaggc
Sequence-based reagentK570G/R571Q/K572T-FPThis paperPCR primerscagacgctgcccaagtacctgct
Sequence-based reagentK570G/R571Q/K572T-RPThis paperPCR primerstccgaagcggaaggccg
Peptide, recombinant proteinrhDAO-WTGludovacz et al., 2016Recombinant human diamine oxidase, wildtype
Peptide, recombinant proteinrhDAO-R568SThis paperR568S mutant of rhDAO-WT
Peptide, recombinant proteinrhDAO-K575TThis paperK575T mutant of rhDAO-WT
Peptide, recombinant proteinrhDAO-R568S/R571TThis paperR568S/R571T mutant of rhDAO-WT
Peptide, recombinant proteinrhDAO-R568S/K575TThis paperR568S/K575T mutant of rhDAO-WT
Peptide, recombinant proteinrhDAO- K570G/R571Q/K572TThis paperK570G/R571Q/K572T mutant of rhDAO-WT
Peptide, recombinant proteinrhFcDAOThis paperHuman IgG Fc-rhDAO fusion protein
Peptide, recombinant proteinrhFcDAO-R568S/R571TThis paperHuman IgG Fc-rhDAO-R568S/R571T fusion protein
Cell line (Cricetulus griseus)CHO-K1_rhDAO-WTGludovacz et al., 2016CHO-K1 stably expressing rhDAO-WT
Cell line (C. griseus)CHO-K1_rhDAO-R568SThis paperCHO-K1 stably expressing rhDAO-R568S
Cell line (C. griseus)CHO-K1_rhDAO-K575TThis paperCHO-K1 stably expressing rhDAO-K575T
Cell line (C. griseus)CHO-K1_rhDAO-R568S/R571TThis paperCHO-K1 stably expressing rhDAO-R568S/R571T
Cell line (C. griseus)CHO-K1_rhDAO-R567S/K575TThis paperCHO-K1 stably expressing rhDAO- R567S/K575T
Cell line (C. griseus)CHO-K1_rhDAO- K570G/R571Q/K572TThis paperCHO-K1 stably expressing rhDAO- K570G/R571Q/K572T
Cell line (C. griseus)CHO-K1_rhFcDAOThis paperCHO-K1 stably expressing rhFcDAO
Cell line (C. griseus)CHO-K1_ rhFcDAO-R568S/R571TThis paperCHO-K1 stably expressing rhFcDAO-R568S/R571T
Cell line (C. griseus)ExpiCHO-SThermo Fisher ScientificCat#: A29133RRID:CVCL_5J31
Cell line (C. griseus)CHO-K1ATCCCat#: CCL-61RRID:CVCL_0214
Cell line (H. sapiens)SK-Hep1Sigma-AldrichCat#: 91091816RRID:CVCL_0525
Cell line (H. sapiens)HUVEC67EvercyteCat#: CPT-006-0067
Cell line (H. sapiens)HUVEC/TERT2EvercyteCat#: CHT-006-0008RRID:CVCL_9Q53
Cell line (H. sapiens)HDMVEC/TERT164-BEvercyteCat#: CHT-013-0164-B
Cell line (H. sapiens)HDF76EvercyteCat#: CPT-008-0076
Cell line (H. sapiens)PODO/TERT256EvercyteCat#: CHT-033-0256RRID:CVCL_JL76
Cell line (H. sapiens)LHCN-M2EvercyteCat#: CkHT-040-231-2RRID:CVCL_8890
Cell line (H. sapiens)HepG2ATCCCat#: HB-8065RRID:CVCL_0027
Cell line (H. sapiens)HeLaEllmeier Lab – Medical University of Vienna
Cell line (H. sapiens)EVTVelicky et al., 2018
AntibodyAnti-ABP1 (rabbit polyclonal)Sigma-AldrichCat#: SAB1410491-100UGIF (1:500)
AntibodyAlexa Fluor 488 anti-rabbit (H + L) (donkey polyclonal)Jackson ResearchCat#: 711-545-152RRID:AB_2313584IF (1:500)
AntibodyIgG serum fraction (rabbit polyclonal)Boehm et al., 2017WB (1:1000)
Antibodyβ-actin mAB (AC-15) (mouse monoclonal)InvitrogenCat#: AM4302RRID:AB_2536382WB (1:5000)
AntibodyIRDye 800CW anti-rabbit IgG (H + L) (goat polyclonal)Li-CorCat#: 926-32211RRID:AB_621843WB (1:5000)
AntibodyIRDye 680RD anti-mouse IgG (H + L) (goat polyclonal)Li-CorCat#: 925-68070RRID:AB_2651128WB (1:5000)
Chemical compound, drugHistamineSigma-AldrichCat#: 53300
Chemical compound, drugHeparinGilvasan1000 IU/mL
Chemical compound, drugHeparin (sodium salt from intestinal mucosa)Sigma-AldrichCat#: H3149
Chemical compound, drugDiminazene aceturateSigma-AldrichCat#: D7770
Commercial assay or kitCisbio HTRF histamine 500 test kitBiomedicaCat#: 62HTMDPET
Commercial assay or kitImmunotech histamine ELISABeckman CoulterCat#: IM2562
Commercial assay or kitExpiCHO Expression System KitThermo Fisher ScientificCat#: A29133
Software, algorithmR (version 3.6.3)R Development Core Team, 2020
Software, algorithmKaluza Flow Cytometry Analysis Software (version 2.1)Beckman Coulter
Software, algorithmImageJ/FijiSchneider et al., 2012
Software, algorithmPymol (version 2.0)The PyMOL Molecular Graphics System, version 2.0 Schrödinger, LLC
Software, algorithmChimeraUCSFAmberTools GUI incorporated
Software, algorithmBIOVIA Discovery Studio 2019Dassault SystemesModeller 9.2 GUI incorporated
Software, algorithmFoldX 4.0Schymkowitz et al., 2005
OtherDAPI stainInvitrogenCat#: D1306(80 ng/mL)
Table 1
Mutuations in the heparin-binding motif of recombinant human diamine oxidase (rhDAO) reduce binding to heparin-sepharose.
rhDAONaClKClMean (SD)
Concentration (mM)Reduction (mM)Concentration (mM)Reduction (mM)Reduction (mM)
WT372031000 (na)
R568S186186172138162 (24)
K575T317552337766 (11)
R568S/R571T175197138172185 (13)
R568S/K575T197175164146161 (15)
K570G/R571Q/K572T*219153---

  1. Purified rhDAO-WT and various HBM mutants were loaded onto a heparin-sepharose column and eluted with linear gradients of 0–1 M NaCl or KCl. The salt concentrations necessary for rhDAO elution and the reduction thereof compared to the wildtype protein are shown. The physiological salt concentration in blood plasma and interstitial fluid is approximately 145 mM.

  2. *

    Corresponds to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster.

  3. HBM = heparin-binding motif; SD = standard deviation; na = not applicable.

Table 2
Recombinant human diamine oxidase (rhDAO) heparin-binding motif mutants eliminate the fast α-distribution half-life and strongly reduce clearance in rats and mice.
rhDAORats IV
AUC (µg/mL/min)*Fold increaset1/2 α (min)t1/2 β (min)
WT1161.03.7250
R568S153113.2na294
R568S/R571T378832.6na353
R568S/K575T211318.242361
Fc-WT691.01.7120
Fc-R568S/R571T272339.5na268
 Mice IVMice IP
AUC (µg/mL/min)†Fold increaset1/2 (min)‡AUC (µg/mL/min)§Fold increaset1/2 (min)‡
WT761.076.141.21.0200
R568S/R571T146819.4192.1666.316.2394
  1. *

    Calculated from 5 to 1440 min.

  2. †

    Calculated from 10 to 1680 min.

  3. ‡

    Calculated from 60 to 1680 min.

  4. §

    Calculated from 0 to 1440 min.

  5. AUC = area under the curve; IV = intravenous; IP = intraperitoneal; na = not applicable.

Table 3
Predicted free energy changes in the human diamine oxidase (hDAO) dimer by mutation of the heparin-binding motif (HBM).
rhDAO mutant variantStabilityAffinity
∆∆G (kcal/mol)∆∆G (kcal/mol)
R568S+0.29+3.50
R571T+0.73+1.96
K575T+2.13+0.55
R568S/R571T+0.60+5.21
R568S/K575T+2.42+3.93
R571T/K575T+2.86+2.52
K570G/R571Q/K572T*+1.53+7.77

  1. The plus sign (+) in the ‘Stability’ column indicates the destabilizing effect on the 3D protein structure, while the plus sign (+) in the ‘Affinity’ column means reduced affinity to heparin hexasaccharide compared to wildtype hDAO. A higher value indicates higher effect on stability or affinity.

  2. *

    Corresponds to the HBM in guinea pig, dog, rat, mouse, and Chinese hamster.

Additional files

Supplementary file 1

The evolutionary conservation analysis of the diamine oxidase (DAO) heparin-binding motif is summarized in Supplementary file 1.

https://cdn.elifesciences.org/articles/68542/elife-68542-supp1-v3.docx
Transparent reporting form
https://cdn.elifesciences.org/articles/68542/elife-68542-transrepform1-v3.docx

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elisabeth Gludovacz
  2. Kornelia Schuetzenberger
  3. Marlene Resch
  4. Katharina Tillmann
  5. Karin Petroczi
  6. Markus Schosserer
  7. Sigrid Vondra
  8. Serhii Vakal
  9. Gerald Klanert
  10. Jürgen Pollheimer
  11. Tiina A Salminen
  12. Bernd Jilma
  13. Nicole Borth
  14. Thomas Boehm
(2021)
Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical
eLife 10:e68542.
https://doi.org/10.7554/eLife.68542